William Mariner Greenman Sells 101,919 Shares of Cerus (NASDAQ:CERS) Stock

Cerus Corporation (NASDAQ:CERS) CEO William Mariner Greenman sold 101,919 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $2.94, for a total transaction of $299,641.86. Following the completion of the transaction, the chief executive officer directly owned 5,053,036 shares in the company, valued at $14,855,925.84. The trade was a 1.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Cerus Stock Performance

NASDAQ CERS opened at $3.16 on Friday. Cerus Corporation has a 52-week low of $1.15 and a 52-week high of $3.21. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.06 and a current ratio of 1.63. The company has a market capitalization of $633.17 million, a P/E ratio of -63.20 and a beta of 1.77. The company has a fifty day moving average of $2.61 and a 200-day moving average of $2.30.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, April 30th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. Cerus had a negative return on equity of 15.18% and a negative net margin of 4.41%.The business had revenue of $59.89 million for the quarter, compared to analysts’ expectations of $55.68 million. As a group, equities research analysts predict that Cerus Corporation will post -0.02 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on CERS. BTIG Research upgraded Cerus from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a research report on Friday, May 1st. Zacks Research upgraded shares of Cerus from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cerus in a research note on Thursday, June 18th. Finally, Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $4.00.

Hedge Funds Weigh In On Cerus

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Cibc World Markets Corp purchased a new stake in shares of Cerus during the fourth quarter valued at approximately $25,000. MML Investors Services LLC purchased a new position in shares of Cerus in the fourth quarter worth $37,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Cerus by 68.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 18,712 shares of the biotechnology company’s stock worth $39,000 after buying an additional 7,603 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in Cerus during the 1st quarter valued at $35,000. Finally, Bingham Private Wealth LLC purchased a new stake in Cerus during the 4th quarter valued at $40,000. 78.37% of the stock is currently owned by institutional investors.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.